Literature DB >> 16565972

Differential expression of VEGF-A and angiopoietins in cartilage tumors and regulation by interleukin-1beta.

Thomas Kalinski1, Sabine Krueger, Saadettin Sel, Kerstin Werner, Martin Ropke, Albert Roessner.   

Abstract

BACKGROUND: Vascular endothelial growth factor (VEGF)-A and angiopoietin (Ang)-1 and Ang-2 are key factors in angiogenic signaling. In this study the expression of these factors was identified in cartilage tumors. As interleukin (IL)-1beta has been found to be an indispensable factor in angiogenic signaling, we further analyzed the effect of IL-1beta on the expression of VEGF-A, Ang-1, and Ang-2 using a previously established cell culture model.
METHODS: Surgical specimens of enchondromas, conventional chondrosarcomas, and dedifferentiated chondrosarcomas were obtained from 72 patients. VEGF-A, Ang-1, and Ang-2 mRNA expression was detected by conventional and quantitative reverse transcription polymerase chain reaction (PCR). VEGF-A expression was also detected by immunohistochemistry or Western blot.
RESULTS: Differential expression of VEGF-A, Ang-1, and Ang-2 was clearly demonstrated in cartilage tumors. VEGF-A expression was positively correlated with the tumor type. Higher VEGF-A expression levels were detected in conventional chondrosarcomas Grades II and III (using a 3-tier grading system) than in dedifferentiated chondrosarcomas (P < .05). A typical pattern of VEGF-A isoforms was identified, including VEGF(121), VEGF(145), VEGF(165), and VEGF(189). Ang-1 presented as a low-level transcript with slightly elevated levels in chondrosarcomas (P < .05). Highly variable Ang-2 expression levels were detected in solitary cases of conventional chondrosarcomas. IL-1beta regulated VEGF-A and Ang-1 expressions in a dose-dependent manner. Whereas low IL-1beta concentrations increased VEGF-A and Ang-1 transcription, high IL-1beta concentrations had the opposite effect. IL-1beta did not activate Ang-2 expression.
CONCLUSIONS: Angiogenic signaling in cartilage tumors is variable and at least partly regulable by IL-1beta. The findings are of therapeutic relevance, either as a desired effect or a side effect in medical treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16565972     DOI: 10.1002/cncr.21848

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

Review 1.  [Inflammation as molecular target in chondrosarcoma].

Authors:  T Kalinski
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

Review 2.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

3.  Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.

Authors:  R Akhavan-Sigari; M R Gaab; V Rohde; A Brandis; H Tezval; M Abili; K von Eckardstein; H Ostertag
Journal:  Neurosurg Rev       Date:  2013-09-03       Impact factor: 3.042

4.  Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma.

Authors:  Bernd Kubista; Florian Klinglmueller; Martin Bilban; Martin Pfeiffer; Richard Lass; Alexander Giurea; Phillipp T Funovics; Cyril Toma; Martin Dominkus; Rainer Kotz; Theresia Thalhammer; Klemens Trieb; Teresa Zettl; Christian F Singer
Journal:  Int Orthop       Date:  2010-03-26       Impact factor: 3.075

5.  [Angiogenesis in cartilage tumors].

Authors:  T Kalinski; A Roessner
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

Review 6.  Systemic Therapy for Chondrosarcoma.

Authors:  Adam Rock; Sana Ali; Warren A Chow
Journal:  Curr Treat Options Oncol       Date:  2022-02-21

7.  Ventricular opening and cerebrospinal fluid circulation accelerate the biodegradation process of carmustine wafers suggesting their immunomodulation potential in the human brain.

Authors:  Ichiyo Shibahara; Yukiko Shibahara; Hiroyuki Hagiwara; Takashi Watanabe; Yasushi Orihashi; Hajime Handa; Madoka Inukai; Takuichiro Hide; Yoshie Yasui; Toshihiro Kumabe
Journal:  J Neurooncol       Date:  2022-07-08       Impact factor: 4.506

8.  Analysis of angiogenic factors and cyclooxygenase-2 expression in cartilaginous tumors- clinical and histological correlation.

Authors:  Francisco Fontes Cintra; Mauricio Etchebehere; José Carlos Barbi Gonçalves; Alejandro Enzo Cassone; Eliane Maria Ingrid Amstalden
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

9.  Curcumin blocks interleukin-1 signaling in chondrosarcoma cells.

Authors:  Thomas Kalinski; Saadettin Sel; Heiko Hütten; Martin Röpke; Albert Roessner; Norbert Nass
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

Review 10.  Chondrosarcoma-from Molecular Pathology to Novel Therapies.

Authors:  Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.